Homology Medicines Reports Third Quarter 2023 Financial Results
- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 -
BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates.
Homology recently shared a summary of safety and efficacy data on the first dose cohort of the pheEDIT clinical trial evaluating the Company’s HMI-103 gene editing candidate for the treatment of phenylketonuria (PKU). Despite the encouraging HMI-103 clinical data, based on the current financing environment and the anticipated clinical development timeline, Homology announced in July 2023 that it would not pursue any further development of its programs, including HMI-103, and instituted a related workforce reduction. Homology further announced that it is evaluating strategic options for the Company, its development programs, including HMI-103, and its platform technology.
The Company retained TD Cowen as its strategic financial advisor and continues to productively advance the process of assessing strategic options.
Third Quarter 2023 Financial Results
About Homology Medicines, Inc.
- Financial Tables Follow -
Keynote Panel: The Continued Rise of AI: Embracing the Known and Unknown to Drive Business Results
Transforming GRC and Cyber Security with AI
Registration Counters Open